This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Raptor Pharmaceutical Corp. Expands Senior Management

NOVATO, Calif., Sept. 10, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced the appointment of Georgia Erbez, as Chief Financial Officer of Raptor, and Julie Anne Smith, as Executive Vice President, Strategy, and Chief Operating Officer.

Ms. Erbez will be responsible for directing Raptor's global financial strategy and organization and providing leadership in defining, communicating, and executing corporate and financial strategic initiatives. Ms. Smith will be responsible for directing Raptor's commercial, manufacturing, and program management organizations, and providing leadership in corporate and strategic development initiatives. Both Ms. Erbez and Ms. Smith will report to Christopher M. Starr, Ph.D, Chief Executive Officer of Raptor.

"We are thrilled to add Georgia and Julie to Raptor's executive management team," stated Christopher Starr, Raptor's CEO. "Their combined skills and experience in strategic finance, orphan drug development and commercialization will greatly enhance our execution capabilities and ability to realize our full growth potential as we anticipate the first approval of our drug for treating cystinosis next year and continue to advance our development programs."

Ms. Erbez has over 20 years of experience in investment banking focused on providing comprehensive financial and strategic advisory services to life science companies. Most recently, Ms. Erbez, as the founder and managing director of Beal Advisors, a boutique investment bank, has provided advisory and capital raising services to emerging growth companies. Ms. Erbez previously worked at Jefferies & Co., SG Cowen, Hambrecht & Quist and Alex. Brown & Sons. Ms. Erbez has participated in over 70 financing and merger transactions in the health care industry valued at over $7.0 billion. Kim Tsuchimoto, who has played a critical role in Raptor's development, will continue in a financial and administrative capacity as Vice President Finance.

Ms. Smith has nearly 20 years of experience in biotech with the preponderance spent in orphan drug development and commercial product opportunities. She has served in executive management of both private and public biotech firms, most recently, as Chief Commercial Officer of Enobia Pharma, Inc., an orphan product clinical stage company acquired by Alexion (Nasdaq:ALXN). Prior to that, she served as Vice President, Commercial, for Jazz Pharmaceuticals, and Vice President Product Development and Global Marketing for Genzyme where she led the worldwide commercialization and planning for Myozyme®, an infused enzyme therapy for ultra-orphan genetic disease.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs